Assay Development for Use in 96-Well Plates
is read in a luminometer. The signal of treated and untreated cells is quantified, allowing calculation of IC 50 values (concentration of drug where 50% of total Her2/ EGFR was degraded).
Assay Development for Use in 96-Well Plates

Antibody Optimization
The success of such an assay requires identification of optimal combinations of cell number, primary and secondary antibodies, blocking and washing buffers. We screened a panel of primary and secondary antibodies searching for a reasonable signal to noise ratio and found the combination of two antibodies obtained form Santa Cruz Biotechnology, the anti-Her2 SC-284, a rabbit polyclonal antibody that binds to the carboxyl terminus region of the protein, and the anti-rabbit SC-2004 to perform excellently in the Her2-blot assay (entry 3, Figure 1A ). The signal resulting from specific antibody binding (white bars, Figure1A) was significantly greater than nonspecific antibody binding to the plate (black bars, Figure 1A ) or cells (gray bars, Figure 1A ). For EGFR, the best signal was obtained with the rabbit polyclonal antibody 06-847 from Upstate Biotechnology (entries 1 and 2, Figure 1B) . Interestingly, the best performing antibodies in the Her2 and EGFR blot also work well in Western blot assays. Cell Number Optimization To test the practicability of our conditions and the accuracy of the Her2/EGFR blot, we tested several agents is a characteristic of the assay itself, without intervention ␤-actin protein levels. We found the BCA assay to be compatible with the Her2-blot reagents. Two 96-well IC 50 values for Her2 degradation obtained by our method were compared to Western blot analysis results.
plates were treated with various concentrations of PU24FCl: the first was subjected to a BCA assay alone, The hsp90 inhibitor, PU24FCl, and the natural products GM and RD gave values in the Her2-blot method identiand the second was subjected to a Her2 blot experiment followed by a BCA assay ( Figure 4A ). Measured differcal to the Western blot assay. Addition of PU24FCl to 
Assay Test in Library Screen
Format ences in total protein between the two plates were insignificant, and an average of 1.5-1.6 g protein was de-
The data presented validate the capability of the assay to quantify the effects of agents that decrease cellular tected in each well. We additionally monitored possible changes in ␤-actin levels due to drug addition, prior to levels of Her2 or EGFR. We further used the assay in a library screen format to identify agents capable of alterand following the Her2 blot ( Figure 4B) . If the ␤-actin blot was performed subsequent to the Her2 blot, plates ing the cellular levels of these kinases. A subset of our hsp90-inhibitor library [14] was added to SKBr3 cells at were stripped and blocked for nonspecific binding prior to the addition of an anti-actin antibody. As expected, a set concentration of 30 M, and the ability of these agents to decrease Her2 levels in cells was determined the levels of actin in the stripped plate were slightly diminished but detectable. Thus, this method, similar after a 6 hr treatment ( Figure 5 and Figure 2B ). Agents that alter cellular levels of kinase by at least 25%-30% to Western blot, allows for reblotting of the plate. No significant differences in actin expression were seen can be considered "hits" with a high degree of confidence ( Figure 2B ). There was no significant change in between untreated and Her2-depleted cells, validating the observation that the lower Her2 levels in treated cells total protein content as determined by the BCA assay; and reliable assay may aid new drug development efforts.
Actin Blot
If the assay was performed previous to the Her2 or EGFR-blots, the Experimental Procedures experiment was conducted as described for the Her2 blot. The anti-␤-actin antibody was purchased from Sigma (AC15) and was used Cell Culture 1:5000 in SuperBlock. The secondary antibody was purchased from The human cancer cell lines SKBr3 and A431 were obtained from the Amersham (NXA931) and used 1:10,000 in SuperBlock. If the assay American Type Culture Collection (Manassas, VA) and maintained in was performed consequently to the Her2 blot, the plates were 1:1 mixture of DME:F12 supplemented with 2 mM glutamine, 50 washed with TBST (2 ϫ 200 l) and stripped with Pierce Stripping units/ml penicillin, 50 units/ml streptomycin, and 5% heat-inactiBuffer (Pierce 21059) (100 l) for 10 min at room temperature. vated fetal bovine serum (FBS) (Gemini Bioproducts) and incubated at 37ЊC in 5% CO 2 . Stock culture was grown in T-175 flasks conTotal Protein taining 30 ml DME (HG, F-12, nonessential amino acids, and penicilTotal protein content was determined using the bicinchoninic acid lin and streptomycin) with glutamine and 10% FBS. Cells were disso-(BCA) reagent (Pierce 23225). Plates resulting from Her2/EGFR blot ciated with 0.05% trypsin and 0.02% EDTA in phosphate buffer readings were washed with TBST (2 ϫ 200 l) and incubated with saline (PBS) without calcium and magnesium.
the BCA reagent (150 l) for 30 min at 37ЊC. Protein concentration GM was obtained from the Developmental Therapeutics Program/ was determined using a standard solution of bovine serum albumin National Cancer Institute, while RD was purchased from Sigma-(BSA). Absorbance was read using a Spectra Max Plus microplate Aldrich. The synthesis of PU24FCl and the purine-based hsp90 lispectrophotometer (Molecular Devices). brary was described elsewhere [13, 14]. All drug stocks were made in DMSO.
Protein Assays Cells were grown to 60%-70% confluence and exposed to drugs or 's t test (2-tailed) 
